Corvus to Start Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA

Plans to initiate soquelitinib potentially registrational Phase 3 clinical trial in Q1 2024

Company to host conference call and webcast tomorrow at 8:30 a.m. ET / 5:30 a.m. PT

Conference Call Details
Corvus will host a conference call and webcast tomorrow, Thursday, September 7, 2023, at 8:30 a.m. ET (5:30 a.m. PT), to discuss the soquelitinib Phase 3 clinical trial plan and other business updates. The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.

https://www.biospace.com/article/releases/corvus-pharmaceuticals-confirms-planned-initiation-of-soquelitinib-cpi-818-phase-3-registrational-clinical-trial-in-peripheral-t-cell-lymphoma-following-meeting-with-fda/